Gilead Stock News

While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of 2023 and li

Most patients are unlikely to develop severe disease or die if they get the current variants of COVID-19 as immunity levels have climbed given higher levels of vaccination.

Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.

Gilead Sciences NASDAQ: GILD share price tanked following the Q3 release on what was otherwise a good report. The company is gaining traction in key markets, sustaining its core business, and offsetti

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Healthca

Gilead Sciences, Inc. (NASDAQ:GILD ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chi

Gilead, eBay and Rivian all beat on the bottom line in Q3, but all three are selling the news.

The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estim

Gilead Sciences (GILD) came out with quarterly earnings of $2.29 per share, beating the Zacks Consensus Estimate of $1.91 per share. This compares to earnings of $1.90 per share a year ago.

Gilead Sciences Inc after Tuesday's close announced third quarter 2023 adjusted earnings per share (EPS) of $2.29, surpassing the analyst consensus forecast of $1.91, according to Zacks Equity Researc

Gilead Sciences Inc.'s GILD, -0.65% stock climbed 2% in extended trading Tuesday after the pharmaceutical company reported quarterly results that topped analyst revenue and earnings estimates. Gilead

Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the American Association for the Study of Liver Diseases (AAS

Gilead Sciences (GILD) closed at $77.88 in the latest trading session, marking a +1.64% move from the prior day.

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.